Tozadenant
Tozadenant (SYN115) is an orally active, selective adenosine A2A receptor antagonist.
In animal models of Parkinson’s disease, tozadenant improves motor neuron function.
Tozadenant (60 mg twice daily) was not associated with a signi cant reduction in o -time, and tozadenant (240 mg twice daily) was associated with an increased rate of discontinuation because of adverse events (17 of 84 patients [20%]). Tozadenant at dose of 120 or 180 mg twice daily was e ective at reducing o -time and was generally well tolerated. Further investigation of tozadenant treatment in phase 3 trials is guaranteed. Perfusion MRI showed that tozadenant induced highly signi cant suppressed in regional cerebral blood ow, with the most important decreases occurring in bilateral thalami.
Reference:
Hauser RA, Olanow CW, Kieburtz KD et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
| Storage | Store at -20°C |
| M.Wt | 406.5 |
| Cas No. | 870070-55-6 |
| Formula | C19H26N4O4S |
| Synonyms | SYN-115;SYN115;SYN 115 |
| Solubility | insoluble in EtOH; insoluble in H2O; ≥20.35 mg/mL in DMSO |
| Chemical Name | 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methylpiperidine-1-carboxamide |
| SDF | Download SDF |
| Canonical SMILES | CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Human experiment [1]: | |
|
Patients |
Patients with Parkinson’s disease. |
|
Dosage form |
60, 120, 180, or 240 mg twice daily for 12 weeks. |
|
Applications |
Tozadenant increases mean daily total on-time and improved total UPDRS scores for parts I-III in the combined tozadenant 120 mg twice-daily and 180 mg twice-daily group and in the 120 mg twice-daily group. Also, tozadenant significantly improved CGI-S and CGI-I scores. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol,2014, 13(8): 767-776. | |
| Description | Tozadenant is an antagonist of adenosine A2A receptor. | |||||
| Targets | adenosine A2A receptor | |||||
| IC50 | ||||||
Quality Control & MSDS
- View current batch:
Chemical structure
